Novartis therapy for infant muscle-wasting disease — potentially carrying a record $2 million price tag — is about to hit market

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 1 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 97%

Business News News

Business Business Latest News,Business Business Headlines

A new treatment for an infant muscle-wasting disease is about to go on sale at a potential cost of $2 million, a record price tag likely to fuel the continuing scrutiny of how companies price their drugs and how insurers pay for them.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Permanent fixes = overpriced. Temporary relief with side effects = underpriced. Dont blame big Pharma. Dont blame insurance companies. Blame every person who pays these companies & says 'that's just how it is.' Everyone is free to make their own choices, except those babies.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 3. in BUSİNESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

A $2 Million Drug Is About to Hit the MarketA new treatment for an infant muscle-wasting disease is about to go on sale at a potential cost of $2 million, a record price tag likely to fuel the continuing scrutiny of how companies price drugs and how insurers pay for it. This should be classified as a human rights violation. I'll take two, please. I don't believe $2 Million is justified. It is Medical Extortion, nothing more!
Source: WSJ - 🏆 98. / 63 Read more »